Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on February 8, 2017, to report its financial results for the quarter and full year ended December 31, 2016. While the 8-K itself does not contain the detailed financial figures, it references a press release (Exhibit 99.1) that provides these results. Investors should refer to this press release for comprehensive information regarding ALNY's financial performance, operational conditions, and any forward-looking statements made by the company. The filing indicates that this information is furnished, not officially filed, under Section 18 of the Exchange Act, meaning it does not carry the same liability implications. However, it is a key disclosure for understanding the company's financial standing at the close of 2016 and should be reviewed in conjunction with other company filings and disclosures.
Key Highlights
- 1Alnylam Pharmaceuticals announced its financial results for the fourth quarter and full year ended December 31, 2016.
- 2The 8-K filing primarily serves as a vehicle to furnish a press release detailing these financial results.
- 3The press release, Exhibit 99.1, is the source for the specific financial performance data and operational condition updates.
- 4Information disclosed in this 8-K (including the press release) is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- 5The filing date is February 8, 2017, indicating the reporting period's close was December 31, 2016.
- 6Investors are directed to Exhibit 99.1 for detailed financial information.